prevalence in several African countries, so that malaria and AIDS are among the most common diseases in sub-Saharan Africa, responsible for several million deaths yearly [2] . Thus, even a small interaction between these 2 diseases might have important public health consequences for many sub-Saharan African countries [3] . Such a link is plausible, when the immunological factors involved in both diseases are considered. Indeed, activated CD4 lymphocytes are the prime target of HIV-1 and play a critical role in malaria immune response [4] . Evidence of the interaction between malaria and HIV-1 infection has been recently reported. HIV-1-infected pregnant women have a higher prevalence of peripheral and placental malaria, higher parasite densities, and more febrile illnesses, severe anemia, and adverse birth outcomes than HIVuninfected women, particularly in multigravidae [5] . HIV-1-infected adults have a higher risk of malaria infection and clinical malaria, the latter increasing with falling CD4 cell count [3, 6] . Plasma HIV-1 load is higher in patients with clinical malaria, and, in some of them, it can be partly reduced by antimalarial treatment [7] [8] [9] . Moreover, in areas of unstable malaria transmission, HIV-1 infection increases the risk of severe malaria in adults [10] . Little is known, however, about the influence that HIV-1 infection has on antimalarial treatment outcome, besides the fact that HIV-1 infection decreases the efficacy of SP intermittent preventive treatment during pregnancy [11, 12] . Few studies have examined the interaction between HIV infection and antimalarial treatment outcome in HIV-1-infected adults [13, 14] , and, to our knowledge, none have assessed the impact of immune suppression in HIV-1-infected patients. Considering that antimalarial treatment outcome is determined not only by the drug's action on the parasite but also by the host's immune response, drug efficacy could be lower in HIV-1-infected patients with malaria, as observed in HIV-1-associated leishmaniasis [15] . We investigated the influence that HIV-1 and HIV-1-induced immune suppression have on the safety and efficacy of antimalarial treatment in a clinical trial.
PATIENTS, MATERIALS, AND METHODS
This study was designed to test the hypothesis that HIV-1 and HIV-1-related immune suppression increase the risk of treatment failure in adult patients with Plasmodium falciparum infection. These assessments were performed during a randomized clinical trial comparing SP and artemether-lumefantrine (AL) (good manufacturing practice-approved AL was provided by the World Health Organization [WHO]). The SP-AL comparison is reported in detail elsewhere [16] .
Study participants. The study was performed between March 2003 and June 2005 at 4 periurban health centers in Ndola, Zambia, an area of mesoendemic malaria where transmission is perennial, with a seasonal peak from November to April. HIV-1 prevalence is estimated at 25.2% among mothers attending the antenatal clinic [17] . In all health centers, voluntary counseling and testing (VCT) activities are established and offered by trained counselors. A reliable ambulance service is available, and patients requiring hospitalization are referred to Ndola Central Hospital, ∼5 km away. All patients aged 15-50 years attending any of the 4 health centers who presented with fever (body temperature, у37.5ЊC) and/or a history of fever in the previous 48 h and who were without any other disease symptoms were screened for malaria infection (by using thick and thin blood film in duplicate for parasite density and species identification) and pregnancy (if applicable). Patients with a P. falciparum density of 25 parasites/200 white blood cells (WBCs) (assumed to be 1000 parasites/mL) or higher were included. Written, informed consent (in English and in the local language), including permission to undergo double-blinded testing for HIV-1 infection (at the central lab), was obtained from each patient before recruitment. Exclusion criteria included the following: pregnancy; severe P. falciparum malaria as defined by WHO criteria [18] ; documented intake of any sulfa drugs, including SP, or AL within the 2 weeks before recruitment; other coinfections; evidence of underlying chronic diseases (cardiac, renal, hepatic, or malnutrition); history of allergy to study drugs or known allergy to other sulfa drugs such as cotrimoxazole; and nonresidence in the study area. The study was approved by the ethics and scientific committees of the Institute of Tropical Medicine, Antwerp, Belgium, and the Tropical Disease Research Centre, Ndola.
Enrollment, treatment, and follow-up. HIV-1 testing followed an "unlinked anonymous" procedure: blood samples were sent to the central lab within a couple of hours, where they were processed anonymously. Neither the study staff nor the patient had access to the HIV test results. Patients wanting to know their HIV-1 status were offered VCT adjacent to the study.
Clinical history, symptoms, and signs including body temperature were recorded, and a blood sample for parasitemia (blood slide) and genotyping (on Schleicher & Schuell filter paper) were collected at day 0 (before treatment) and days 3, 7, 14, 21, 28, and 45 after treatment or at any unscheduled visit. The blood sample on filter paper was dried at room temperature and stored at Ϫ20ЊC with silica gel. At day 0, 3 mL of venous blood was collected for hemoglobin (Hb) measurement, HIV testing, and CD4 cell count assessment. Hb was measured again at days 14 and 45. Patients were encouraged to attend the health facility outside scheduled visits if they felt ill. Treatment failures with SP (clinical or parasitological) were treated with AL, whereas treatment failures with AL were treated with quinine. Adverse events (AES) were treated accordingly and recorded. Patients were excluded from further study follow-up if they had taken any other drug with antimalarial activity or if they withdrew the informed consent.
Laboratory investigations. All laboratory technicians were blinded to the patients' identities and all patient-related parameters. Thin blood films were fixed with methanol, and thin and thick blood films were stained with 10% Giemsa. At the clinic, the number of asexual P. falciparum parasites per 200 WBCs was determined. Parasite density per microliter was computed, taking into account the actual WBC counts. Internal quality control was organized as recommended by WHO [18] . Hb was measured by use of HaemoCue (HaemoCue) at days 0, 14, and 45. Patients were tested for HIV by use of the Abbott Determine test (Abbot). If negative, the patient was considered to be HIV-1 uninfected. If the sample was positive, a second test, Genie II (BioRad), was performed. If the result was discordant with the previous test (i.e., negative), then a final test, CAPILLUS 1/2 (Biognost), was done and considered as the final result. CD4 cell count was assessed on all HIV-1-infect- n p 321 b Data on white blood cell counts were missing for 5 HIV-1-uninfected and 6 HIV-1-infected patients. c CD4 cell count data missing for 52 (16%) HIV-1-infected patients. d Sample sizes: uninfected, ; infected, . n p 638 n p 320 e Jaundice and pallor specifically observed in 302 HIV-1-infected and 301 HIV-1-uninfected patients.
ed patients, by direct volumetric absolute counting (Cyflow Counter; Partec) [19] . A FACSCount machine (Becton Dickinson) was used to validate the Cyflow data and served as a backup. Blood samples collected on filter paper at enrollment and during follow-up were used to genotype parasite strains; only those microscopically positive after day 14 were analyzed. DNA was purified as described elsewhere [20] , and a nested polymerase chain reaction (PCR) for the analysis of 2 polymorphic P. falciparum genetic markers, MSP1 and MSP2 repeat region, was performed. A recrudescent infection was defined as one that showed a match in size of at least 1 allele for both the MSP1 and MSP2 genes between the first and second sample. More details on treatment-allocation procedures, followup procedures, and outcome definitions can be found elsewhere [16] .
Assessment of outcome.
The primary end point was PCRcorrected clinical and parasitological outcome at day 45 according to HIV status. Outcomes were defined in accordance with the most recent WHO classification (2003): early treatment failure, late clinical failure, late parasitological failure, and adequate clinical and parasitological response. All AEs were recorded on the case record form. An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the drug administered. A causality assessment of the AEs was done in accordance with the guidelines of the WHO-Uppsala Monitoring Centre.
Statistical analysis. Data were double entered and cleaned in Epi Info (version 6.04b; Centers for Disease Control and Prevention). Proportions were compared using the x 2 or Fisher's exact tests (when required); Student's t test was used for continuous variables. A paired t test was used for within-patient comparisons. Nonnormally distributed variables were transformed, or nonparametric tests (Wilcoxon or Kruskal-Wallis) were used. The log-rank test and the proportional hazard were estimated (after the Schoenfeld test). In the proportional hazard regression, all patients were censored at the time of the last recorded visit. Stepwise multivariate analyses were performed, and all possible interactions up to order 2 were tested. All reported P values are 2-sided. All analyses were performed using the STATA statistical analysis software package (version 9; Stata Corp.).
RESULTS

Baseline characteristics of the patients.
A total of 971 patients, of whom 33.0% (320/971) were HIV-1 infected, were enrolled and randomized for treatment with either SP (486) ), had a lower WBC count ( vs. ), and had a slightly higher mean body tem-P p .02 perature at enrollment (37.3ЊC vs. 37.2ЊC;
). Parasite P p .02 density was similar in both groups, and gametocyte prevalence did not differ significantly. The median CD4 cell count in HIV-1-infected patients was 256 cells/mL; in 58.7% (95% confidence interval [CI], 53.0%-64.9%) of HIV-1-infected patients, the CD4 cell count was !300 cells/mL (table 1). The proportion of patients complaining of diarrhea ( ) and backache ( P ! .001 P ! ) was significantly higher among HIV-1-infected patients. .001
Body temperature was significantly associated with higher parasite density ( ), regardless of the HIV-1 status. In P ! .001 HIV-1-infected patients, CD4 cell counts tended to be inversely related to parasite density ( ) and body temperature P p .06 ( ) .
Trial profile. Thirty-five (3.6%) patients were lost to follow-up by day 3, and 120 (12.4%) were lost to follow-up by day 45; 12 (1.2%) patients withdrew from the study, and 9 (0.9%) were excluded (4 were hospitalized for reasons not linked to malaria or study treatment, and 5 took other antimalarial drugs) (figure 1). Population movement was the main reason (180%) for withdrawal and loss to follow-up. Patients excluded or lost to follow-up were younger than those who reached a study end point ( ). Other demographic and P ! .001 clinical characteristics, including HIV-1 infection prevalence and CD4 cell count, were similar to those of the patients reaching a study end point ( and ). P p .82 P p .55 HIV-1-infected versus HIV-1-uninfected patients. Gametocyte and parasite clearance were similar in both groups throughout follow-up, but the proportion of patients with fever was significantly higher in HIV-1-infected patients up to day 7 after treatment. Among patients with no recurrent parasitemia, HIV-1-infected patients remained significantly more anemic both at day 14 and day 45 (table 2) . HIV-1-infected patients had more diarrhea and felt weaker up to day 14 after treatment. Backache was reported more often in HIV-1-infected patients throughout follow-up (table 2) .
Serious adverse events were observed in 2 HIV-1-infected patients (both with CD4 cell counts !300 cells/mL). One, treated with SP, was hospitalized on day 2 for severe headache and received quinine, and the other, treated with AL, developed a rash on the first day.
HIV ). The latter had a risk for re-P p .01 current parasitemia that was similar to that of HIV-1-uninfected patients (RR, 0.68 [95% CI, 0.35-1.34];
). The P p .28 risk of recurrent parasitemia was significantly higher in HIV-1-infected patients with malaria with a CD4 cell count !300 cells/mL (RR, 1.69 [95% CI, 1.20-2.39];
) than in the P p .002 other patients in the study.
Among HIV-1-infected patients and after PCR correction, the risk of recrudescence tended to be higher (RR, 1.84 [95% CI, 0.94-3.59];
) in those with a CD4 cell count !300 P p .09 cells/mL than in patients with a CD4 cell count у300 cells/mL (table 3) . The latter had a risk for recrudescence that was similar to that of HIV-1-uninfected patients (RR, 0.93 [95% CI, 0.51-
1.70];
). The risk of recrudescence was significantly P p .81 higher in HIV-1-infected patients with malaria with a CD4 cell count !300 cells/mL (RR, 1.67 [95% CI, 1.13-2.47]; ) P p .02 than in the other patients in the study. The relationship between CD4 cell count and recrudescence was not confounded by age or treatment regimen. Overall, 77.6% (76/98) of the recrudescence occurred after treatment with SP, the least efficacious drug in this trial.
After PCR correction, the risk of reinfection tended to be higher (RR, 6.09 [95% CI, 0.81-46.0]; ) in patients with P p .07 a CD4 cell count !300 cells/mL than in those with a CD4 cell count у300 cells/mL. HIV-1-infected patients with malaria with a CD4 cell count у300 cells/mL had a risk of reinfections (RR, 0.23 [95% CI: 0.03-1.64];
) that was similar to P p .10 that of HIV-1-uninfected patients. Only 1 of 94 HIV-1-infected patients with malaria with a CD4 cell count у300 cells/mL had recurrent parasitemia identified as a reinfection. Despite the fact that the risk of reinfections (RR, 1.67 [95% CI, 0.76-3.65];
) was similar to that of recrudescence when HIV-1-P p .20 infected patients with a CD4 cell count !300 cells/mL were compared with all the other patients, this did not reach statis- [95% CI, 0.85-52.9]; ) tended to be associated with low P p .07 CD4 cell count. The cumulative hazard rates are shown in figure  2 . On day 45, the cumulative hazard rate for recrudescence reached 0.374 per person in patients with a CD4 cell count !300 cells/mL, compared with 0.113 per person in those with a CD4 cell count у300 cells/mL.
DISCUSSION
HIV-1-infected patients did not have a higher risk of recurrent parasitemia than did HIV-1-uninfected ones. However, within the HIV-1-infected group, recurrent parasitemia tended to be inversely related to CD4 cell count. Patients with a CD4 cell count !300 cells/mL were more likely to have recurrent parasitemia, recrudescence, and new infection alike. The impact that HIV-1-induced immune suppression has on malaria treatment outcome progressively increases as the drug efficacy decreases. Indeed, most of the recrudescences were found in the SP group. This is, to our knowledge, the first report on the influence that CD4 cell count has on the outcome of antimalarial treatment in HIV-1-infected patients with malaria.
Compared with the HIV-1-uninfected patients, HIV-1-infected patients with malaria in the present study were older, and women were more represented. This finding is consistent with the epidemiological profile of HIV-1 in Zambia [17] . However, in the present study, the proportion of HIV-1-infected adult patients with malaria (58.7%) with a CD4 cell count !300 cells/mL was higher than that of the general HIV-1-infected adult population in Zambia [17] .
Our findings confirm previous results showing that HIV-1 infection has no significant impact on malaria treatment outcome in children [21] [22] [23] [24] [25] . Nevertheless, a recent study performed in Uganda in 50 HIV-1-infected adult patients reported differences between HIV-1-infected and -uninfected patients [14] similar to those we observed between HIV-1-infected patients with a low CD4 cell count and HIV-1-uninfected ones. Most probably, because of the low power and the shorter fol-low-up period of 28 days, the risk of recrudescence did not reach significance. The similarity between these findings could be explained by a high proportion of Ugandan patients with a low CD4 cell count. The declining HIV-1 epidemic in Uganda (prevalence among adults fell from a peak of 13% in the early 1990s to an estimated 4.1% in 2003 [26] ) and the relatively high median age (28.5 years) of the Ugandan study participants suggest an important proportion of HIV-1 infections of long duration in individuals with a low CD4 cell count. Therefore, the observed interaction between HIV-1 infection and antimalarial treatment might vary from country to country and on the basis of the proportion of patients with malaria with low CD4 cell counts.
HIV-1-infected patients with a CD4 cell count у300 cells/ mL had a recrudescence rate similar to that of HIV-1-uninfected patients but, surprisingly, a lower number of new infections. The significance of this finding is unclear.
Although HIV infection as such did not influence the risk of treatment failure, some symptoms, such as weakness, diarrhea, and backache, persisted longer in the HIV-1-infected patients. Because HIV-1 infection is associated with various opportunistic infections, the sustained fever and symptoms in HIV-1-infected patients with a positive malaria slide could be due to a concomitant disease [23, 27] .
Our data add to the evidence that HIV-1-infected patients with suppressed immunity (CD4 cell count, !300 cells/mL) represent, next to children and pregnant women, an additional vulnerable group for malaria [4] [5] [6] [7] [8] [9] 13] . The use of cotrimoxazole preventive therapy (CPT), an antifolate with antimalarial activities, in immunosuppressed HIV-1-infected patients [28] is a current recommendation. This policy, if widely implemented, might decrease the malaria burden [29] . However, although the data available do not suggest that CPT has an influence on the efficacy of other antifolates [30] , cross-resistance between cotrimoxazole and other antifolates used as antimalarials, such as SP, has been reported [31] [32] [33] . Furthermore, it should be considered that the scaling up of antiretroviral treatment might interfere with the physiopathological mechanisms in the case of protease inhibitors [34] or treatment of malaria. Indeed, antiretrovirals and antimalarials might follow the same metabolic pathways and, by interacting, affect treatment efficacy or toxicity when taken simultaneously. Such potential interaction should be carefully evaluated.
HIV-1-infected patients with clinical malaria represent a substantial proportion of adult patients attending health facilities in regions where malaria and HIV infection coexist. Beyond the direct effects that HIV-1 infection has on malaria incidence and malaria treatment failure, rising incidence of HIV-1-associated febrile illnesses could increase antimalarial drug pressure [3, 35] . The inadequate parasite clearance in immune compromised HIV-1-infected patients, combined with the increased drug pressure, might contribute to the emergence and spread of antimalarial drug resistance. Indeed, inadequate parasite clearance results in delayed response to treatment, increased recrudescence with shortening of the average period between clinical attacks, and further spread of resistant strains [36] . This is a major concern because antimalarial drug resistance is now generally acknowledged to be one of the greatest threats to our ability to reduce the burden of malaria [37] .
